ReNeuron Group - Edison Group

Overview
Price performance
Financials
Research
Sector insights
Thematics

ReNeuron is a UK biotech company developing allogeneic cell therapies. The first pivotal Phase IIb trial for CTX neural stem cells for chronic stroke disability is underway. Human retinal progenitor cells (hRPCs) are also being studied for RP (in Phase I/IIa).

Latest Insights

View More

Healthcare |
Update

27.11.23

ReNeuron Group — H124 results reaffirm focus on CustomEX

Healthcare |
Flash note

15.09.23

ReNeuron Group — A step forward on the Exosome delivery platform

Healthcare |
Update

30.05.23

ReNeuron Group — Full steam ahead with CustomEx

Flash note

09.12.22

ReNeuron Group — Encouraging data for iPSCs opens potential

ReNeuron-Group_resized

Sector

Healthcare

Balance Sheet

Forecast net debt (£m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	0.0	(20.6)	(69.3)
Relative	(0.6)	(22.5)	(68.1)
52 week high/low	10.8p/3.4p

Financials

Edison Investment Research is terminating coverage on ReNeuron Group (RENE). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Mar	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (fd) (p)	P/E (x)	P/CF (x)
2022A	0.4	N/A	(11.1)	(17.01)	N/A	N/A
2023A	0.5	N/A	(6.7)	(9.47)	N/A	N/A
2024E	N/A	N/A	N/A	N/A	N/A	N/A
2025E	N/A	N/A	N/A	N/A	N/A	N/A

Update

Healthcare

15.01.21

ReNeuron Group — Continuing to gain clinical data in eye disease

Update

Healthcare

08.12.20

ReNeuron Group — Funding to complete Phase IIa and other projects

Outlook

Healthcare

26.08.20

ReNeuron Group — Exploiting the potential of cell therapy

Update

Healthcare

06.07.20

ReNeuron Group — Strong data in retinal therapy shows long effects

Update

Healthcare

23.06.20

ReNeuron Group — Focus on retinal therapy, out-licensing of stroke

Update

Healthcare

26.02.20

ReNeuron Group — Stable 12-month vision

Update

Healthcare

10.02.20

ReNeuron Group — Zero overhang

Outlook

Healthcare

19.12.19

ReNeuron Group — A transformational year

Update

Healthcare

17.07.19

ReNeuron Group — FY19 prelims after a momentous second half

Update

Healthcare

20.05.19

ReNeuron Group — Year-end update highlights transaction potential

Flash note

Healthcare

26.04.19

ReNeuron Group — Early clinical data in RP continue to improve

Update

Healthcare

11.04.19

ReNeuron Group — Long-awaited partnering floodgates open

Update

Healthcare

22.02.19

ReNeuron Group — Exciting positive data in retinitis pigmentosa (RP)

Flash note

Healthcare

24.01.19

ReNeuron Group — Formative event

Flash note

Healthcare

04.01.19

ReNeuron Group — Open season on Exosome deals

Outlook

Healthcare

21.12.18

ReNeuron Group — Time to reflect

Flash note

Healthcare

20.07.18

ReNeuron Group — Exosomes rise further

Update

Healthcare

13.07.18

ReNeuron Group — US exclusivity deal – more than non-dilutive cash

Update

Healthcare

22.05.18

ReNeuron Group — The rise of the exosome

Update

Healthcare

14.02.18

ReNeuron Group — Consolidation confusion?

Update

Healthcare

21.12.17

ReNeuron Group — Biblical aspirations

Update

Healthcare

06.07.17

ReNeuron Group — Milestones expected as pipeline progresses

research

Healthcare

06.07.17

ReNeuron Group — Clinical pipeline progressing as planned

Update

Healthcare

02.05.17

ReNeuron Group — Global clinical pipeline strategy update

Outlook

Healthcare

23.03.17

ReNeuron Group — Clinical pipeline progressing as planned

edison tv

Healthcare

19.12.16

Executive Interview – ReNeuron

Update

Healthcare

07.12.16

ReNeuron Group — Update 7 December 2016

Update

Healthcare

05.08.16

ReNeuron Group — Update 5 August 2016

Outlook

Healthcare

27.07.16

ReNeuron Group — Update 27 July 2016

edison tv

Healthcare

19.07.16

Executive Interview – ReNeuron

Update

Healthcare

24.03.16

ReNeuron — Update 24 March 2016

edison tv

Healthcare

22.10.14

Executive Interview – ReNeuron